1,2,4-Trimethoxybenzene

Synonyms: 羟基氢醌三甲醚
1,2,4-Trimethoxybenzene 是一种口服有效的 NLRP3 选择性抑制剂,可显著抑制 Nigericin (MS-O56514) 或 ATP (MS-D18391) 诱导的 NLRP3 炎症小体活化,从而降低 caspase-1 活化和 IL-1β 分泌,并特异性抑制 NLRP3 炎症小体活化而不影响黑色素瘤缺失 2 (AIM2) 炎症小体活化,同时通过抑制凋亡相关斑点样蛋白 (ASC) 寡聚化以及 NLRP3 与 ASC 之间的蛋白-蛋白相互作用来阻断 NLRP3 炎症小体组装,因此可用于研究实验性自身免疫性脑脊髓炎 (EAE)、多发性硬化症和 2 型糖尿病。
产品编号: MS-F25088 CAS No.: 135-77-3 分子式: C9H12O3 分子量: 168.19
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
50mg
询价
询价
100mg
询价
询价
250mg
询价
询价

产品描述

1,2,4-Trimethoxybenzene 是一种口服有效的 NLRP3 选择性抑制剂,可显著抑制 Nigericin (MS-O56514) 或 ATP (MS-D18391) 诱导的 NLRP3 炎症小体活化,从而降低 caspase-1 活化和 IL-1β 分泌,并特异性抑制 NLRP3 炎症小体活化而不影响黑色素瘤缺失 2 (AIM2) 炎症小体活化,同时通过抑制凋亡相关斑点样蛋白 (ASC) 寡聚化以及 NLRP3 与 ASC 之间的蛋白-蛋白相互作用来阻断 NLRP3 炎症小体组装,因此可用于研究实验性自身免疫性脑脊髓炎 (EAE)、多发性硬化症和 2 型糖尿病。

生物实验数据

生物活性 1,2,4-Trimethoxybenzene is an orally active selective NLRP3 inhibitor that significantly suppresses Nigericin (MS-O56514)- or ATP (MS-D18391)-induced NLRP3 inflammasome activation, thereby reducing caspase-1 activation and IL-1β secretion, specifically inhibits NLRP3 inflammasome activation without affecting melanoma absent in 2 (AIM2) inflammasome activation, and blocks NLRP3 inflammasome assembly by inhibiting apoptosis-associated speck-like protein (ASC) oligomerization and the protein-protein interaction between NLRP3 and ASC, and can therefore be used to study experimental autoimmune encephalomyelitis (EAE), multiple sclerosis, and type 2 diabetes.
IC50 & Target

NLRP3

 

Caspase-1

 

IL-1β

 

体外研究
(In Vitro)

1,2,4-Trimethoxybenzene (0.5-1 mM,1.5 h) 显著抑制 Nigericin 和 Lipopolysaccharides (MS-X54539) (LPS) 诱导的永生化小鼠骨髓来源巨噬细胞 (iBMDM) 中 NLRP3 炎症小体的激活,表现为 caspase-1 (Casp-1) 裂解和 IL-1β 分泌减少。
1,2,4-Trimethoxybenzene (1 mM,75-90 分钟) 抑制 LPS 和 ATP 诱导的 iBMDM、原代小胶质细胞和原代巨噬细胞中 NLRP3 的激活。
1,2,4-Trimethoxybenzene (45 分钟-2 小时) 不抑制 LPS 和 poly(dA:dT) 诱导的原代腹腔巨噬细胞和 Ibmdm 中 AIM2 炎症小体的激活。
1,2,4-Trimethoxybenzene (1小时) 可减少 LPS 和 Nigericin 诱导的 iBMDM 和原代小胶质细胞中 ASC 斑点的形成:免疫荧光显示 ASC 斑点数量显著减少;DSS 交联实验显示可溶性 ASC 增加,不溶性 ASC 减少。
1,2,4-Trimethoxybenzene (1小时) 可阻断 LPS 诱导的 iBMDM 中 NLRP3 与 ASC 之间的蛋白-蛋白相互作用。
1,2,4-Trimethoxybenzene (1 小时) 抑制 LPS 和 Nigericin 诱导的 iBMDM 和原代巨噬细胞的 NLRP3 寡聚化:DSS 交联实验表明 NLRP3 单体、二聚体和更高寡聚体的形成减少。

Western Blot Analysis

Cell Line: Immortalized murine bone marrow-derived macrophages (iBMDMs)
Concentration: 0.5 mM, 1 mM
Incubation Time: 1.5 h
Result: Caspase-1 (Casp-1) cleavage and IL-1β secretion are reduced.
体内研究
(In Vivo)

1,2,4-Trimethoxybenzene (200 mg/kg,口服,每日一次,持续 17 天) 可显著缓解 EAE 模型小鼠的临床症状、体重减轻和脱髓鞘病理。
1,2,4-Trimethoxybenzene (50-100 mg/kg,口服,每日一次,连续 3 天) 可通过抑制 NLRP3 炎症小体,增强小鼠恐惧记忆的消退,并缓解创伤后应激障碍 (PTSD) 相关的焦虑和抑郁样行为。
1,2,4-Trimethoxybenzene (50-200 mg/kg,口服,每日一次,连续 8 周) 可通过抑制 NLRP3 炎症小体的激活和调节 2 型糖尿病大鼠的肠道菌群,改善相关的认知功能障碍。

Animal Model: Female C57BL/6 mice (6-8 weeks old) were subcutaneously injected with 150 μg of MOG35-55 peptide, and intraperitoneally injected with 200 ng of pertussis toxin on the day of immunization (day 0) and day 2, to simulate EAE.
Dosage: 200 mg/kg
Administration: P.o., once daily for 17 days
Result: The incidence of end-stage renal disease (ESRD) decreased, and clinical symptoms were significantly alleviated.
Significantly reduced weight loss indicates a reduction in systemic inflammatory response.
The area of myelin basic protein (MBP) positive in spinal cord sections was significantly larger than in the control group, indicating a reduced degree of demyelination.
The percentage of demyelinated area was significantly lower than in the control group, confirming the protection of myelin structure.
ASC specks were significantly reduced in spinal cord sections, suggesting that NLRP3 inflammasome activation was inhibited.
The expression of NLRP3, ASC, and cleaved caspase-1 proteins was downregulated in spinal cord tissue.
The mRNA expression of pro-inflammatory cytokines IFN-γ and IL-17a and the chemokine CCL-5 was decreased in the spinal cord, while the expression of the anti-inflammatory cytokine IL-4 was upregulated.
Animal Model: Male C57BL/6 mice (8 weeks old) were intraperitoneally injected with lipopolysaccharide (LPS, 2 mg/kg/d) for 3 consecutive days to induce depressive-like behavior.
Dosage: 50 mg/kg, 100 mg/kg
Administration: P.o., once daily for 3 days
Result: Sucrose preference was significantly increased (with improved depressive-like behavior), and immobility time in the tail suspension test (TST) and forced swimming test (FST) was significantly reduced.
Activation of the hippocampal NLRP3 inflammasome was inhibited (e.g., reduced expression of cleaved IL-1β, cleaved caspase-1, and ASC spot formation).
Animal Model: Male Sprague-Dawley rats (8 weeks old, 200 g) were first given a high-sugar, high-fat diet for 5 weeks, and then type 2 diabetes (T2DM) was induced by intraperitoneal injection of streptozotocin (STZ, 30 mg/kg).
Dosage: 50 mg/kg, 100 mg/kg, 200 mg/kg
Administration: P.o., once daily for 8 weeks
Result: Significant improvements were observed in blood glucose levels (FBG, OGTT-AUC), insulin resistance index (HOMA-IR), and blood lipids (TC, TG, LDL-C) in rats, along with a decrease in oxidative stress markers (MDA).
Shortened escape latency and increased target quadrant time indicate enhanced learning and memory abilities.
Improved neuronal structure was observed in the hippocampal CA1 region, with ELISA detecting elevated BDNF levels and decreased AChE levels in the hippocampus.
Inhibition of the hippocampal NLRP3 inflammasome pathway (e.g., reduced expression of NLRP3, ASC, caspase-1, GSDMD, and IL-1β).
性状 液体

化学信息

分子量 168.19
分子式 C9H12O3
CAS No. 135-77-3
别名 羟基氢醌三甲醚

储存&溶解度

储存方式

Store at room temperature 3 years

In solvent -80°C 2 years
-20°C 1 year
运输条件 Room temperature in continental US; may vary elsewhere.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础